Cisatracurium Besylate Injection
Product Images NDC 31722-313

This text provides important information about a pharmaceutical product called Cisatracurium Besylate Injection, USP, with a concentration of 10 mg/5 mL. It is a paralyzing agent for intravenous injection and comes in a single-dose vial. The product should be stored refrigerated at 2° to 8°C and protected from light, with a warning that it can cause respiratory arrest. Facilities must have artificial respiration available immediately. The product does not contain benzyl alcohol or preservatives and must be discarded after use. Additionally, it provides manufacturing information for Camber Pharmaceuticals, Inc. in Piscataway, NJ, and Aspiro Pharma Limited in Telangana, India.*

This text contains detailed information about a medication called Cisatracurium Besylate Injection, USP. It warns that the medication is a paralyzing agent that can cause respiratory arrest. The solution is sterile, nonpyrogenic, and intended for intravenous injection. Each mL contains 2 mg of cisatracurium. The text provides a contact number for inquiries, storage instructions, expiration date, and manufacturing details. It is important to note the warning labels and storage conditions to ensure the safe use of this medication.*

This text describes a medication named cisatracurium besylate, an injectable solution with a concentration of 10 mg/mL, used as a paralyzing agent for intravenous injection. The medication comes in a 20 mL single-dose vial and must be used carefully due to its nature as a respiratory arrest-inducing agent. It is sterile, nonpyrogenic, and should be stored refrigerated at 2° to 8°C. The medication is manufactured for Camber Pharmaceuticals, Inc., and manufactured by Aspiro Pharma Limited in India. It also mentions that the medication is benzyl alcohol-free and preservative-free, and any unused portion should be discarded properly.*

This is a description of Cisatracurium Besylate Injection, a medication intended for intravenous use in ICU settings. It is benzyl alcohol and preservative-free, containing cisatracurium 10 mg per mL. Each vial holds 20 mL of single-dose solution. The medication acts as a paralyzing agent and requires immediate availability of respiration facilities. Storage instructions include refrigeration at 2° to 8°C and protection from light. After removal from refrigeration, the medication must be used within 21 days, even if placed back in the refrigerator. The manufacturer is Camber Pharmaceuticals, Inc., based in Piscataway, NJ, USA, and it is made by Aspiro Pharma Limited in Telangana, India. Additionally, the text includes the manufacturer's license number and details as issued in August 2025.*

This is an evaluation of percentages: 60% for 4 hours and around 60%.*

This is a description of Cisatracurium Besylate Injection, USP (2 mg/mL), a paralyzing agent used for intravenous injection. The medication is supplied in a 10 mL multiple-dose vial containing 0.9% benzyl alcohol as a preservative. It should be refrigerated at 2° to 8°C, and protected from light. Once removed from refrigeration, it should be used within 21 days. Artificial respiration facilities must be readily available as the medication can cause respiratory arrest. The product is sterile, nonpyrogenic, and manufactured by Aspiro Pharma Limited for Camber Pharmaceuticals, Inc. in India. Contact information and expiration details are provided for proper disposal and usage.*